High-dose prophylactic anticoagulation or therapeutic anticoagulation reduced de novo thrombosis in patients with hypoxemic COVID-19 pneumonia, based on data from 334 adults. Patients with hypoxemic ...
Phenotype-guided dosing strategies can increase the proportion of patients with hematologic malignancies who achieve a therapeutic drug concentration of prophylactic voriconazole, according to results ...
NEW ORLEANS — A therapeutic vs. prophylactic dose of anticoagulation therapy did not significantly improve outcomes for noncritically ill patients hospitalized with COVID-19, though fewer therapeutic ...
BARCELONA, Spain—New results from three trials presented here at the European Society of Cardiology Congress 2022 have provided additional insights into what works—and what doesn’t—for addressing the ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...
In the randomized controlled COVID-PACT trial, full-dose heparin had a 95% greater likelihood of benefit for a composite of fatal and nonfatal thrombotic endpoints compared with standard prophylactic ...
High-dose methotrexate (HDMTX) is an antineoplastic dosing strategy used to treat various cancers including primary central nervous system lymphoma. Trimethoprim-sulfamethoxazole (TMP/SMX) is commonly ...
Obesity is associated with an increased risk of VTE, and it has been postulated that standard prophylactic LMWH doses may be insufficient to prevent VTE or achieve suggested anti-factor Xa target ...
Therapeutic-dose anticoagulation primarily consisting of rivaroxaban (Xarelto; Bayer/Janssen), compared with standard thromboprophylaxis, does not improve outcomes in patients hospitalized with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results